Panacea Biotec: Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Revi ew Report for…
Panacea Biotec (PANACEABIO) filed a disclosure titled "Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Revi ew Report for the quarter and half - year ended September 30, 2026". The company is valued at about ₹2,214…
What happened
Panacea Biotec (PANACEABIO) filed a disclosure with the exchanges on 14 November 2026 at 08:31 PM titled "Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Revi ew Report for the quarter and half - year ended September 30, 2026".
From the filing: "Saturday , November 14 , 2026 , inter - alia, considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half - year ended September 30, 2026 ."
Company snapshot
Panacea Biotec is a small-cap company, with a market value of about ₹2,214 crore.
The stock last traded at ₹361.5, against a 52-week range of ₹292.4–₹647 (44.1% below the high).
Before this filing the shares had moved +3.4% over the month and −12.7% over three months. Average daily turnover over the last 20 sessions was about ₹1.78 crore.
Promoters held 72.48% at the end of Q1 FY27. Foreign institutions owned 2.31% and domestic institutions 2.25%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 167 | 4.1 | 0.66 |
| Q2 FY26 | 141 | -13.9 | -2.27 |
| Q3 FY26 | 165 | 4 | 0.65 |
| Q4 FY26 | 167 | 0.5 | 0.08 |
| Q1 FY27 | 200 | 2.3 | 0.38 |
What history shows
This is not the company's first results disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 2.8% on average the next trading day and was up 22.4% on average after five days (3 filings with price data).
Market-wide, 11,811 results filings with an impact score of 50 or more saw an average next-day move of −0.2%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 13 Aug 2026 | , the financial results for the period ended Jun 30, 2026. | −0.3% | −0.7% |
| 31 May 2026 | Audited Financial Results For Quarter And Financial Year Ended March… | +4.3% | +33.9% |
| 30 May 2026 | Board Meeting Outcome for 1. Standalone And Consolidated Audited… | +4.3% | +33.9% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 14 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.